Home / Stocks / CLBT

Cellebrite DI (CLBT, Application Software) Stock Valuation & Fair Value Significantly overvalued

Cellebrite DI (CLBT, Application Software) trades at a blended P/E of 42.2, about 51% above its historical normal valuation, with a forward growth estimate of 22.3% and a PEG of 1.89. Priced at its historical normal P/E of 27.9 on the same blended earnings, the 2026-09-18 close of $11.62 corresponds to about $7.69 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
42.2
Normal P/E
27.9
PEG
1.89
Fwd growth
22.3%
Div yield
0.0%
RSI (14)
45.5
Neutral

The Street vs SeerForecast

Wall Street's mean price target for CLBT is $15.36 across 7 analysts, 33.5% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-08-07.

Blended P/E and rating by weekBlended P/E moved from 49.9 to 42.2 between 2026-08-07 and 2026-09-21, against a normal P/E of 27.9, with 0 rating changes over 16 recorded weeks.2026-08-07: P/E 49.9, Significantly overvalued (recalculated)2026-08-10: P/E 51.6, Significantly overvalued2026-08-14: P/E 51.6, Significantly overvalued (recalculated)2026-08-17: P/E 39.8, Significantly overvalued2026-08-21: P/E 39.8, Significantly overvalued (recalculated)2026-08-24: P/E 39.6, Significantly overvalued2026-08-27: P/E 39.6, Significantly overvalued (recalculated)2026-08-28: P/E 39.6, Significantly overvalued (recalculated)2026-08-30: P/E 39.6, Significantly overvalued (recalculated)2026-08-31: P/E 43.1, Significantly overvalued2026-09-05: P/E 43.1, Significantly overvalued (recalculated)2026-09-07: P/E 41.3, Significantly overvalued2026-09-12: P/E 41.3, Significantly overvalued (recalculated)2026-09-14: P/E 40.6, Significantly overvalued2026-09-19: P/E 40.6, Significantly overvalued (recalculated)2026-09-21: P/E 42.2, Significantly overvalued30.040.050.0Aug 7Aug 18Aug 29Sep 10Sep 21Normal P/E 27.9
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-08-07P/E 49.9+79%Significantly overvalued
2026-08-10P/E 51.6+85%Significantly overvalued
2026-08-24P/E 39.6+42%Significantly overvalued
2026-09-21P/E 42.2+51%Significantly overvalued ← now

Frequently asked questions

Is Cellebrite DI stock overvalued?

At a blended P/E of 42.2 versus its historical normal P/E of 27.9, Cellebrite DI trades about 51% above its typical valuation, with a PEG of 1.89 on 22.3% forward growth. tickerseer currently rates it significantly overvalued.

What is Cellebrite DI's fair value and PEG?

Cellebrite DI trades at a blended P/E of 42.2 against a historical normal P/E of 27.9, a PEG of 1.89, and a forward growth estimate of 22.3%. Priced at its historical normal P/E of 27.9 on the same blended earnings, the 2026-09-18 close of $11.62 corresponds to about $7.69 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Cellebrite DI changed?

tickerseer's rating has been significantly overvalued since 2026-08-07.

What is the analyst price target for Cellebrite DI?

The mean Wall Street price target for Cellebrite DI is $15.36 across 7 analysts, 33.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Application Software. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track CLBT free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.